'We Jumped' At Opportunity To Take On Pfizer's CAR-T Program, Allogene's Chang Says
Former Kite exec David Chang is keen to use smaller firm's focus to advance allogeneic therapy more rapidly. The start-up acquired Pfizer R&D team along with its allogeneic CAR-T programs and related IP.
You may also be interested in...
Private Company Edition: Sirnaomics planned to go public after its series D, but its new venture capital does not prevent it from doing so in the near term. Also, Vida Ventures and Novalis Biotech raised new VC funds to back start-ups and ArriVent launched with up to $150m in series A cash.
Shaw cites manufacturing speed and success as competitive edges. The Gilead subsidiary unveiled data at ASCO positioning Tecartus, its second CAR-T therapy, to add B-cell acute lymphoblastic leukemia to label.
Chris Boshoff, Pfizer Oncology chief development officer, said lessons from the rapid pace of the company’s COVID-19 vaccine program are being applied to elranatamab and other cancer therapies.